INS and metabolic dysfunction-associated steatotic liver disease: In this clinical study, Fouqueray and colleagues demonstrate that PXL70 inhibits hepatic lipogenesis and improves glucose metabolism and insulin sensitivity in non-alcoholic fatty liver disease patients.